Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01686620 · ClinicalTrials.gov registry record · Phase 2
A Study Evaluating Safety and Efficacy of BIOD-123 Compared to Insulin Lispro (Humalog®)
A Phase 2 study, sponsored by Biodel.
- Completed
- Registry status
- Phase 2
- Development phase
- 132
- Enrollment target
NCT01686620 is a Phase 2 study that has completed, run by Biodel. The registered enrollment target is 132 participants.
The verdict
NCT01686620, a Phase 2 study, has completed, sponsored by Biodel.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 132 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of BIOD-123 compared to insulin lispro (Humalog®) when used as part of a basal-bolus regimen in patients with type 1 diabetes.
Interventions
- DRUG BIOD-123
- DRUG Lispro (Humalog)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2012-08 |
| Est. Completion | 2013-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01686620
The ClinicalTrials.gov registry entry for NCT01686620 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 132 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biodel, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BIOD-123 is the first listed.
NCT01686620 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01686620 about?
NCT01686620 is a clinical study titled "A Study Evaluating Safety and Efficacy of BIOD-123 Compared to Insulin Lispro (Humalog®)". The purpose of this study is to evaluate the safety and efficacy of BIOD-123 compared to insulin lispro (Humalog®) when used as part of a basal-bolus regimen in patients with type 1 diabetes.
What is the current status of trial NCT01686620?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 132 participants. The study started on 2012-08. Estimated completion is 2013-06.
What interventions are being tested in trial NCT01686620?
The interventions under investigation include: BIOD-123 (DRUG), Lispro (Humalog) (DRUG).
Who is sponsoring clinical trial NCT01686620?
This trial is sponsored by Biodel, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.